Literature DB >> 23822136

Mechanisms of impaired differentiation in rhabdomyosarcoma.

Charles Keller1, Denis C Guttridge.   

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, with presumed skeletal muscle origins, because of its myogenic phenotype. RMS is composed of two main subtypes, embryonal RMS (eRMS) and alveolar RMS (aRMS). Whereas eRMS histologically resembles embryonic skeletal muscle, the aRMS subtype is more aggressive and has a poorer prognosis. In addition, whereas the genetic profile of eRMS is not well established, aRMS is commonly associated with distinct chromosome translocations that fuse domains of the transcription factors Pax3 and Pax7 to the forkhead family member FOXO1A. Both eRMS and aRMS tumor cells express myogenic markers such as MyoD, but their ability to complete differentiation is impaired. How this impairment occurs is the subject of this review, which will focus on several themes, including signaling pathways that converge on Pax-forkhead gene targets, alterations in MyoD function, epigenetic modifications of myogenic promoters, and microRNAs whose expression patterns in RMS alter key regulatory circuits to help maintain tumor cells in an opportunistically less differentiated state.
© 2013 FEBS.

Entities:  

Keywords:  MyoD; differentiation; microRNA; myogenesis; rhabdomyosarcoma; signaling

Mesh:

Year:  2013        PMID: 23822136      PMCID: PMC6250433          DOI: 10.1111/febs.12421

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  116 in total

1.  Topical topics: Brain cancer incidence in children: time to look beyond the trends.

Authors:  J G Gurney
Journal:  Med Pediatr Oncol       Date:  1999-08

Review 2.  Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications.

Authors:  P L Puri; V Sartorelli
Journal:  J Cell Physiol       Date:  2000-11       Impact factor: 6.384

3.  Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation.

Authors:  Asoke K Mal
Journal:  EMBO J       Date:  2006-07-13       Impact factor: 11.598

4.  JmjC-domain-containing proteins and histone demethylation.

Authors:  Robert J Klose; Eric M Kallin; Yi Zhang
Journal:  Nat Rev Genet       Date:  2006-09       Impact factor: 53.242

5.  Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.

Authors:  P N Tonin; H Scrable; H Shimada; W K Cavenee
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

6.  Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.

Authors:  F J Lejeune; N Pujol; D Liénard; F Mosimann; W Raffoul; A Genton; L Guillou; M Landry; P G Chassot; R Chiolero; A Bischof-Delaloye; S Leyvraz; R O Mirimanoff; D Bejkos; P F Leyvraz
Journal:  Eur J Surg Oncol       Date:  2000-11       Impact factor: 4.424

7.  MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.

Authors:  Zhihong Yang; Kyle L MacQuarrie; Erwin Analau; Ashlee E Tyler; F Jeffery Dilworth; Yi Cao; Scott J Diede; Stephen J Tapscott
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

8.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

9.  TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.

Authors:  Daniela Palacios; Chiara Mozzetta; Silvia Consalvi; Giuseppina Caretti; Valentina Saccone; Valentina Proserpio; Victor E Marquez; Sergio Valente; Antonello Mai; Sonia V Forcales; Vittorio Sartorelli; Pier Lorenzo Puri
Journal:  Cell Stem Cell       Date:  2010-10-08       Impact factor: 24.633

10.  miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells.

Authors:  Kyle L Macquarrie; Zizhen Yao; Janet M Young; Yi Cao; Stephen J Tapscott
Journal:  Skelet Muscle       Date:  2012-04-29       Impact factor: 4.912

View more
  55 in total

1.  SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Authors:  Davide Martino Coda; Marcello Francesco Lingua; Deborah Morena; Valentina Foglizzo; Francesca Bersani; Ugo Ala; Carola Ponzetto; Riccardo Taulli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

3.  HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.

Authors:  Yanfeng Li; Jesse Bakke; David Finkelstein; Hu Zeng; Jing Wu; Taosheng Chen
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

4.  The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.

Authors:  Michael D Deel; Katherine K Slemmons; Ashley R Hinson; Katia C Genadry; Breanne A Burgess; Lisa E S Crose; Nina Kuprasertkul; Kristianne M Oristian; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2018-03-07       Impact factor: 12.531

5.  Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.

Authors:  Meiling Zhang; Bo Zhu; Judith Davie
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

6.  MyoD Regulates Skeletal Muscle Oxidative Metabolism Cooperatively with Alternative NF-κB.

Authors:  Jonathan Shintaku; Jennifer M Peterson; Erin E Talbert; Jin-Mo Gu; Katherine J Ladner; Dustin R Williams; Kambiz Mousavi; Ruoning Wang; Vittorio Sartorelli; Denis C Guttridge
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

Review 7.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

8.  Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma.

Authors:  Madeline N Hayes; Karin McCarthy; Alexander Jin; Mariana L Oliveira; Sowmya Iyer; Sara P Garcia; Sivasish Sindiri; Berkley Gryder; Zainab Motala; G Petur Nielsen; Jean-Paul Borg; Matt van de Rijn; David Malkin; Javed Khan; Myron S Ignatius; David M Langenau
Journal:  Cell Stem Cell       Date:  2018-03-01       Impact factor: 24.633

9.  Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.

Authors:  Silvia Codenotti; Maura Poli; Michela Asperti; Daniela Zizioli; Francesco Marampon; Alessandro Fanzani
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-03       Impact factor: 4.553

10.  Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.

Authors:  Francesca Bersani; Marcello Francesco Lingua; Deborah Morena; Valentina Foglizzo; Silvia Miretti; Letizia Lanzetti; Giovanna Carrà; Alessandro Morotti; Ugo Ala; Paolo Provero; Roberto Chiarle; Samuel Singer; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto; Riccardo Taulli
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.